Abpro (ABP) Stock Analysis

What Abpro does

Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.

Key metrics

ETFs linked to ABP

Broad-market and Healthcare sector ETFs an investor holding Abpro is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ABP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Abpro?

Abpro trades under the ticker ABP on NASDAQ.

Which exchange is ABP listed on?

ABP is listed on NASDAQ.

What sector does Abpro operate in?

Abpro is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ABP in a portfolio?

PortView shows ABP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.